67 related articles for article (PubMed ID: 3406046)
1. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
Smith EF; McDonald J
Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
Shirakura S; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
[TBL] [Abstract][Full Text] [Related]
3. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
Smith EF; Jugus M; Kinter LB
Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
[TBL] [Abstract][Full Text] [Related]
4. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
Lefer DJ; Mentley RK; Lefer AM
Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
8. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
Patscheke H; Stegmeier K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
[No Abstract] [Full Text] [Related]
9. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
Schumacher WA; Heran CL
J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
[TBL] [Abstract][Full Text] [Related]
10. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
11. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
12. Influence of SK&F 96148 on thromboxane-mediated responses in the airways of the cat.
Dyson MC; Kadowitz PJ
Eur J Pharmacol; 1991 May; 197(1):17-25. PubMed ID: 1909957
[TBL] [Abstract][Full Text] [Related]
13. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
[No Abstract] [Full Text] [Related]
14. Characterization of contraction-mediating prostanoid receptors in human hand veins: effects of the thromboxane receptor antagonists BM13,505 and AH23848.
Arner M; Högestätt ED; Uski TK
Acta Physiol Scand; 1991 Jan; 141(1):79-86. PubMed ID: 2053448
[TBL] [Abstract][Full Text] [Related]
15. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
Karasawa A; Shirakura S; Higo K; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
[TBL] [Abstract][Full Text] [Related]
16. Modulation of renin by thromboxane: studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic.
Welch WJ; Wilcox CS; Dunbar KR
Am J Physiol; 1989 Oct; 257(4 Pt 2):F554-60. PubMed ID: 2508488
[TBL] [Abstract][Full Text] [Related]
17. The strong contractile effect of the thromboxane receptor agonist U-46619 in isolated human pulmonary arteries and its competitive antagonism by BM-13.505.
Sjöberg T; Steen S
Acta Physiol Scand; 1989 Jun; 136(2):161-5. PubMed ID: 2528885
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death.
Ma XL; Karasawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane agonism and antagonism in a mouse sudden death model.
Myers A; Penhos J; Ramey E; Ramwell P
J Pharmacol Exp Ther; 1983 Feb; 224(2):369-72. PubMed ID: 6822961
[TBL] [Abstract][Full Text] [Related]
20. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2.
Braun M; Schrör K
Stroke; 1990 Dec; 21(12 Suppl):IV152-4. PubMed ID: 2260141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
